Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Diabetologia. 2013 Aug 10;56(11):10.1007/s00125-013-3009-7. doi: 10.1007/s00125-013-3009-7

Fig. 2.

Fig. 2

Effect of B2AR agonist systemic administration on counter-regulatory hormones during the hypoglycaemic clamp. Plasma glucagon (a), adrenaline (b) and noradrenaline (c) concentrations. Grey bars, B2AR agonist; white bars, controls. Results are presented as means ± SEM